Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD

ClinicalTrials.gov ID: NCT06011577

Public ClinicalTrials.gov record NCT06011577. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).

Study identification

NCT ID
NCT06011577
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Levomecor Inc.
Industry
Enrollment
27 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 16, 2023
Primary completion
Dec 18, 2024
Completion
Dec 18, 2024
Last update posted
Jul 9, 2026

2023 – 2024

United States locations

U.S. sites
36
U.S. states
16
U.S. cities
35
Facility City State ZIP Site status
Relmada Site Dothan Alabama 36303
Relmada Site Homewood Alabama 35209
Relmada Site Anaheim California 92805
Relmada Site Lafayette California 94549
Relmada Site Newport Beach California 92660
Relmada Site Orange California 92868
Relmada Site Redlands California 92374
Relmada Site Sherman Oaks California 91403
Relmada Site Farmington Connecticut 06030
Relmada Site Brandon Florida 33511
Relmada Site Hialeah Florida 33027
Relmada Site Jacksonville Florida 32256
Relmada Site Miami Florida 33133
Relmada Site Miami Florida 33174
Relmada Site Okeechobee Florida 34972
Relmada Site Tampa Florida 33607
Relmada Site Springfield Illinois 62794
Relmada Site Baltimore Maryland 21208
Relmada Site Mankato Minnesota 56001
Relmada Site Toms River New Jersey 08755
Relmada Site Brooklyn New York 11235
Relmada Site Cedarhurst New York 11516
Relmada Site New York New York 10036
Relmada Site Philadelphia Pennsylvania 19104
Relmada Site Franklin Tennessee 37067
Relmada Site Memphis Tennessee 38119
Relmada Site Austin Texas 78712
Relmada Site Bellaire Texas 77401
Relmada Site Friendswood Texas 77546
Relmada Site Houston Texas 77030
Relmada Site Wichita Falls Texas 76309
Relmada Site Clinton Utah 84015
Relmada Site Draper Utah 84020
Relmada Site Rutland Vermont 05701
Relmada Site Charlottesville Virginia 22903
Relmada Site Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06011577, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 9, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06011577 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →